Cargando…
Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies
BACKGROUND AND OBJECTIVES: Blinatumomab (BLINCYTO(®)) is a novel bispecific T cell engager (BiTE(®)) approved in the USA for the treatment of relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL) in children and adults, as well as minimal residual disease ALL in adults. This ana...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109194/ https://www.ncbi.nlm.nih.gov/pubmed/31679130 http://dx.doi.org/10.1007/s40262-019-00823-8 |